Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Artigo em Inglês | IMSEAR | ID: sea-157625

RESUMO

The H1N1 influenza A infection initially pandemic started in Mexico in March 2009 and spread as per WHO phases of pandemic alert all over the world. It was in late march 2009 an outbreak of a respiratory illness and later to proved to be caused by novel swine origin influenza A (S-OIV) identified in Mexico. Aims & Objectives : The aim of the present study was to describe first clinical presentation, various organ damage, treatment outcome duration of hospital stay and mortality and impact on high risk group patients. This is retrospective study hospital based Bharati Vidyapeeth Deemed University Medical College and Hospital, Sangli. Material and Methods: During post-pandemic period in 2010 the patients were admitted in hospitals which were suspected cases of H1N1 influenza “A” infection. 118 cases were studied August 2010 to 31st January 2011. Results : One hundred eighteen (118) patients were admitted in hospital. Of the 118 patients 32 patients were H1N1 positive and 86 patients H1N1 negative. RT- PCR test was done for confirmation of infection. X- Ray chest in positive cases of H1N1 influenza “A” infection bilateral extensive Pneumonititis other organ damage suggestive ECG, STT were changes renal failure common symptoms cough, fever, breathlessness in 28 cases sex-wise and age-wise distribution is not significant. Hospital stay all admitted patients and hospital stay in expired patients p value < 0.00 and < 0.005 highly significant. Statistics – percentage, ratio Chi- square tests used. Conclusion : Mortality in risk (Comorbid condition) with and without risk (ventilator required) The Mortality was 18.50 % more during the winter season (Chilly and cold atmosphere August to October during this season feverable for viability of the virus) significantly mortality is seen in young age group. This infection can be prevented by vaccination. The tablet tamiflu 75 mg 1 BD for 10 days no other adverse effects observed in our study the drug is safe and no resistance was observed.


Assuntos
Adulto , Feminino , Humanos , Vírus da Influenza A Subtipo H1N1 , Influenza Humana/complicações , Influenza Humana/diagnóstico , Influenza Humana/tratamento farmacológico , Influenza Humana/epidemiologia , Influenza Humana/diagnóstico por imagem , Masculino , Mortalidade , Síndrome do Desconforto Respiratório/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA